Next Article in Journal
Long Term Results of Two-Stage Revision for Chronic Periprosthetic Hip Infection: A Multicenter Study
Previous Article in Journal
Posterior Oblique Square Decompression with a Three-Step Wanding Technique in Tubular Minimally Invasive Transforaminal Lumbar Interbody Fusion: Technical Report and Mid-Long-Term Clinical Outcomes
Previous Article in Special Issue
Clinical Evidence of Cannabinoids in Migraine: A Narrative Review
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 11
Issue 6
10.3390/jcm11061656
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

New Generation Gepants: Migraine Acute and Preventive Medications

by
David Moreno-Ajona
1,2,
María Dolores Villar-Martínez
1,2 and
Peter J. Goadsby
1,2,3,*
1
Basic and Clinical Neurosciences, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London SE5 9PJ, UK
2
NIHR-Wellcome Trust King’s Clinical Research Facility/SLaM Biomedical Research Centre, King’s College Hospital, London SE5 9RS, UK
3
Department of Neurology, University of California, Los Angeles, CA 90095, USA
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2022, 11(6), 1656; https://doi.org/10.3390/jcm11061656
Submission received: 15 February 2022 / Accepted: 23 February 2022 / Published: 16 March 2022
(This article belongs to the Special Issue Prevention and Acute Treatment of Migraine)
Review Reports Versions Notes

Abstract

Migraine is a debilitating disease whose clinical and social impact is out of debate. Tolerability issues, interactions, contraindications, and inefficacy of the available medications make new options necessary. The calcitonin-gene-related peptide (CGRP) pathway has shown its importance in migraine pathophysiology and specific medications targeting this have become available. The first-generation CGRP receptor antagonists or gepants, have undergone clinical trials but their development was stopped because of hepatotoxicity. The new generation of gepants, however, are efficacious, safe, and well tolerated as per recent clinical trials. This led to the FDA-approval of rimegepant, ubrogepant, and atogepant. The clinical trials of the available gepants and some of the newer CGRP-antagonists are reviewed in this article.
Keywords: gepants; CGRP; acute medications; painkillers; migraine gepants; CGRP; acute medications; painkillers; migraine

Share and Cite

MDPI and ACS Style

Moreno-Ajona, D.; Villar-Martínez, M.D.; Goadsby, P.J. New Generation Gepants: Migraine Acute and Preventive Medications. J. Clin. Med. 2022, 11, 1656. https://doi.org/10.3390/jcm11061656

AMA Style

Moreno-Ajona D, Villar-Martínez MD, Goadsby PJ. New Generation Gepants: Migraine Acute and Preventive Medications. Journal of Clinical Medicine. 2022; 11(6):1656. https://doi.org/10.3390/jcm11061656

Chicago/Turabian Style

Moreno-Ajona, David, María Dolores Villar-Martínez, and Peter J. Goadsby. 2022. "New Generation Gepants: Migraine Acute and Preventive Medications" Journal of Clinical Medicine 11, no. 6: 1656. https://doi.org/10.3390/jcm11061656

APA Style

Moreno-Ajona, D., Villar-Martínez, M. D., & Goadsby, P. J. (2022). New Generation Gepants: Migraine Acute and Preventive Medications. Journal of Clinical Medicine, 11(6), 1656. https://doi.org/10.3390/jcm11061656

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop